{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:22:10Z","timestamp":1771867330160,"version":"3.50.1"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> To estimate the cost\u2010effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN\/DEX) for the treatment of relapsed\/refractory multiple myeloma in Sweden.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We used partitioned survival analysis to assess survival data decomposed into three states: (i) alive before disease progression; (ii) alive after progression; and (iii) dead. The effects of treatment on time to progression and overall survival (OS) were obtained from published reports of the APEX, MM\u2010009, and MM\u2010010 randomized clinical trials. Costs included drug and administration costs, adverse events, treatment of relapses, and end\u2010of\u2010life costs. Utility estimates were derived from the literature.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> BTZ mean OS was 57.4\u2003months compared with 44.6 and 54.1\u2003months for DEX and LEN\/DEX, respectively. Mean lifetime direct medical costs per patient were approximately 2010 SEK 1\u2003904\u2003462, 1\u2003278\u2003854, and 2\u2003450\u2003588 for BTZ, DEX, and LEN\/DEX, respectively. Mean incremental cost per quality\u2010adjusted life\u2010year of BTZ compared to DEX was 2010 SEK 902,874 (\u20ac95\u2003073) (95% CI: 514\u2003791, 962\u2003416) and was dominant with respect to LEN\/DEX.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> BTZ and LEN\/DEX are projected to prolong survival relative to DEX. From a Swedish perspective, BTZ is cost\u2010effective compared to DEX and LEN\/DEX.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01526.x","type":"journal-article","created":{"date-parts":[[2010,9,16]],"date-time":"2010-09-16T06:38:25Z","timestamp":1284619105000},"page":"484-491","source":"Crossref","is-referenced-by-count":27,"title":["The cost\u2010effectiveness of bortezomib in relapsed\/refractory multiple myeloma: Swedish perspective"],"prefix":"10.1111","volume":"85","author":[{"given":"John","family":"Hornberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Rickert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravinder","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Liwing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Aschan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"L\u00f6thgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0100"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20652"},{"key":"e_1_2_6_4_2","unstructured":"Multiple Myeloma Research Foundation.Multiple Myeloma Research Foundation. Newly diagnosed patients: What is multiple myeloma?http:\/\/www.themmrf.org\/living\u2010with\u2010multiple\u2010myeloma\/newly\u2010diagnosed\u2010patients\/what\u2010is\u2010multiple\u2010myeloma\/. cited January 19 2009."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.17"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000216008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.147"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2307\/2684631"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-8-621"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604501"},{"key":"e_1_2_6_15_2","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond M","year":"1997"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:1:65"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(10)65776-2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199712010-00009"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.019"},{"key":"e_1_2_6_21_2","unstructured":"The Southern Regional Health Care Board.Prices and Reimbursements for the Southern Health Care Region 2006. Lund Sweden.http:\/\/www.srvn.org. cited August 31 2009."},{"key":"e_1_2_6_22_2","unstructured":"The Swedish Institute for Health Economics.Technical report 2007\u201003\u201005 rev 2007\u201008\u201023. A report on resource utilization and costs for Swedish patients treated for multiple myeloma.2007."},{"key":"e_1_2_6_23_2","unstructured":"Millenium Pharmaceuticals I.Addendum to Final Clinical Study Report M341\u2010CSR\u2010003 VELCADE\u2122 (bortezomib) for Injection submitted to US Food and Drug Administration (FDA) and to the European Agency for the Evaluation of Medicinal Products (EMEA). (Section 9.1 page 43). Aug 3 2005."},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","unstructured":"FASS.se. K\u00e4llan till kunskap om l\u00e4kemedel 2009;http:\/\/www.fass.se\/. cited February 19 2009.","DOI":"10.1016\/j.giec.2008.12.002"},{"key":"e_1_2_6_25_2","unstructured":"FASS.L\u00e4kemedel I Sverige V L\u00e4kemedelsinformation AB (Pharmaceutical Information)Stockholm 2008 http:\/\/www.fass.se. cited December 22 2008."},{"key":"e_1_2_6_26_2","unstructured":"The Pharmaceutical Benefits Board Decision: Revlimid application for inclusion in pharmaceutical reimbursement scheme (reference 2274\/2007). Solna Sweden;2008."},{"key":"e_1_2_6_27_2","unstructured":"LFNAR.General guidelines for economic evaluations from the Pharmaceutical Benefits Board;2003."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0074-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1588"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1561::AID-CNCR18>3.0.CO;2-W"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05186.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.09.003"},{"key":"e_1_2_6_34_2","unstructured":"World Health Organization (WHO).Table: threshold values for intervention cost\u2010effectiveness by region.2009.http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/index.html. cited February 19 2009."},{"key":"e_1_2_6_35_2","first-page":"3436","article-title":"och sjukv\u00e5rden beh\u00f6ver kunskap om hur befolkningen v\u00e4rderar h\u00e4lsan","volume":"100","author":"Persson U","year":"2003","journal-title":"L\u00e4kartidningen"},{"key":"e_1_2_6_36_2","unstructured":"Central Intelligence Agency.The World Fact book \u2013 Sweden. 2008 December 18;https:\/\/www.cia.gov\/library\/publications\/the\u2010world\u2010factbook\/geos\/sw.html. cited January 20 2009."},{"key":"e_1_2_6_37_2","unstructured":"Lakemedelsformansnamnden. (LFN) 1154\/2006; 2007 February 20."},{"key":"e_1_2_6_38_2","unstructured":"Lakemedelsformansnamnden. (LFN) 1154\/2006; 2008 February 25."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01526.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T08:38:56Z","timestamp":1698655136000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01526.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01526.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01526.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}